Contraception
Volume 73, Issue 2 , Pages 195-204 , February 2006

Progestogen-only contraceptive use among women with sickle cell anemia: a systematic review

Received 27 July 2005 ,Accepted 11 August 2005.

References 

  1. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151:839–845
  2. Freie HM. Sickle cell diseases and hormonal contraception. Acta Obstet Gynecol Scand. 1983;62:211–217
  3. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute . Facts about sickle cell anemia. Rockville (MD): National Institutes of Health; 2004;
  4. Fort AT, Morrison JC, Diggs LW, Fish SA, Berreras L. Counseling the patient with sickle cell disease about reproduction: pregnancy outcome does not justify the maternal risk. Am J Obstet Gynecol. 1971;111:324–327
  5. Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol. 2001;184:1127–1130
  6. Howard RJ, Tuck SM. Contraception and sickle cell disease. IPPF Med Bull. 1994;28:3–4
  7. Lutcher CL. Blood coagulation studies and the effect of oral contraceptives in patients with sickle cell anemia. Clin Res Southern Soc Hematol. 1976;24:47a
  8. Evans DK. Sickle cells and hormonal contraception. Br J Fam Plann. 1984;10:80–81
  9. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: World Health Organization; 2004;
  10. Koshy M. Sickle cell disease and pregnancy. Blood Rev. 1995;9:157–164
  11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490
  12. Ladipo OA, Falusi AG, Feldblum PJ, Osotimehin BO, Otolorin EO, Ojengbede OA. Norplant use by women with sickle cell disease. Int J Gynecol Obstet. 1993;41:85–87
  13. Barbosa IC, Ladipo OA, Nascimento ML, et al. Carbohydrate metabolism in sickle cell patients using a subdermal implant containing nomegestrol acetate (Uniplant). Contraception. 2001;63:263–265
  14. Nascimento ML, Ladipo OA, Coutinho E. Nomegestrol acetate contraceptives implant use by women with sickle cell disease. Clin Pharmacol Ther. 1998;64:433–438
  15. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997;56:313–316
  16. De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet. 1982;2:229–231
  17. Yoong WC, Tuck SM, Yardumian A. Red cell deformability in oral contraceptive pill users with sickle cell anaemia. Br J Haematol. 1999;104:868–870
  18. Howard RJ, Lillis C, Tuck SM. Contraceptives, counselling, and pregnancy in women with sickle cell disease. BMJ. 1993;306:1735–1737
  19. Adadevoh BK, Isaacs WA. The effect of megestrol acetate on sickling. Am J Med Sci. 1973;265:367–370

PII: S0010-7824(05)00319-7

doi: 10.1016/j.contraception.2005.08.010

Contraception
Volume 73, Issue 2 , Pages 195-204 , February 2006

Article Tools